FDA Inspection 1029693 — Mezgebe Berhe, MD
The FDA completed an inspection of Mezgebe Berhe, MD on September 29, 2017 in Dallas, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 29, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Dallas, TX (United States)
Additional Details
Clinical Investigator (CI)